Home › Research › Prevention and risk
Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies
Olmastroni E, Molari G, De Beni N, Colpani O, Galimberti F, Gazzotti M, Zambon A, Catapano AL et al.. European journal of preventive cardiology, 2022-05-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Aims As the potential impact of statins on cognitive decline and dementia is still debated, we conducted a meta-analysis of observational studies to examine the effect of statin use on the risk of Alzheimer's disease (AD) and dementia. Methods and results PubMed, Cochrane, and EMBASE were searched since inception to January 2021. Inclusion criteria were: (i) cohort or case-control studies; (ii) statin users compared to non-users; and (iii) AD and/or dementia risk as outcome. Estimates from original studies were pooled using restricted maximum-likelihood random-effect model. Measure of effects were reported as odds ratio (OR) and 95% confidence intervals (CIs). In the pooled analyses, statins were associated with a decreased risk of dementia [36 studies, OR 0.80 (CI 0.75-0.86)] and of AD [21 studies, OR 0.68 (CI 0.56-0.81)]. In the stratified analysis by sex, no difference was observed in the risk reduction of dementia between men [OR 0.86 (CI 0.81-0.92)] and women [OR 0.86 (CI 0.81-0.92)]. Similar risks were observed for lipophilic and hydrophilic statins for both dementia and AD, while high-potency statins showed a 20% reduction of dementia risk compared with a 16% risk reduction associated with low-potency statins, suggesting a greater efficacy of the former, although a borderline statistical significance (P = 0.05) for the heterogeneity between estimates. Conclusion These results confirm the absence of a neurocognitive risk associated with statin treatment and suggest a potential favourable role of statins. Randomized clinical trials with an ad hoc design are needed to explore this potential neuroprotective effect.
What this study adds
Evidence grade: High
This is a pooled review. This meta-analysis of observational studies found that statin use was associated with a decreased risk of dementia and of Alzheimer's disease. Reported effect size: OR 0.80; OR 0.68; OR 0.86.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Olmastroni, E., Molari, G., De Beni, N., Colpani, O., Galimberti, F., Gazzotti, M., et al. (2022). Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies. European journal of preventive cardiology. https://doi.org/10.1093/eurjpc/zwab208
Vancouver
Olmastroni E, Molari G, De Beni N, Colpani O, Galimberti F, Gazzotti M, et al. Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies. European journal of preventive cardiology. 2022. doi:10.1093/eurjpc/zwab208. PMID: 34871380.
BibTeX
@article{olmastroni2022-34871380,
author = {Olmastroni, E. and Molari, G. and De Beni, N. and Colpani, O. and Galimberti, F. and Gazzotti, M. and Zambon, A. and Catapano, A. L. and others},
title = {{Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies}},
journal = {European journal of preventive cardiology},
year = {2022},
doi = {10.1093/eurjpc/zwab208},
pmid = {34871380},
url = {https://doi.org/10.1093/eurjpc/zwab208}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Methods and results PubMed, Cochrane, and EMBASE were searched since inception to January 2021.
- Inclusion criteria were: (i) cohort or case-control studies; (ii) statin users compared to non-users; and (iii) AD and/or dementia risk as outcome.
- In the pooled analyses, statins were associated with a decreased risk of dementia [36 studies, OR 0.80 (CI 0.75-0.86)] and of AD [21 studies, OR 0.68 (CI 0.56-0.81)].
- Similar risks were observed for lipophilic and hydrophilic statins for both dementia and AD, while high-potency statins showed a 20% reduction of dementia risk compared with a 16% risk reduction associated with low-potency statins, suggesting a greater efficacy of the former, although a borderline statistical significance (P = 0.05) for the heterogeneity between estimates.
- Conclusion These results confirm the absence of a neurocognitive risk associated with statin treatment and suggest a potential favourable role of statins.
Why it matters
This meta-analysis of observational studies found that statin use was associated with a decreased risk of dementia and of Alzheimer's disease. Because it pools observational studies, it cannot show that statins prevent or treat Alzheimer's disease.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Study designmeta-analysis
- Effect sizeOR 0.80; OR 0.68; OR 0.86
- Evidence strengthHigh
How this study scored 64/100
Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. Scored zero for sample size and studied in people because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (European journal of preventive cardiology) |
| Journal's citation record | 1 / 4 | European Journal of Preventive Cardiology: journal h-index 133 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A meta-analysis pooling many studies |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 5 / 7 | Cited 196 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 32.7 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 3 / 6 | Cited 5.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 8 other studies in this library |
| Still being cited | 3 / 4 | Cited 155 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Manuela Casula: h-index 34 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Padua: institution h-index 1,158 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 34871380) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 64 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1093/eurjpc/zwab208
- PubMed: 34871380
- Original source →
- Free full text: European Journal of Preventive Cardiology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
8 studies in the alzhub library list this one in their references.